CJC-1295 and Gabapentin Interaction: What You Need to Know

What Is the CJC-1295 and Gabapentin Interaction?

The interaction between CJC-1295 and gabapentin is primarily pharmacodynamic, not pharmacokinetic. Both agents can depress central nervous system activity through different mechanisms, and when used together, their sedating effects may add together. CJC-1295 does not inhibit CYP450 enzymes or P-glycoprotein, so it will not raise gabapentin blood levels directly. The clinically relevant risk is layered CNS depression, especially in patients who are also taking opioids, benzodiazepines, or sleep aids.

How CJC-1295 Works

CJC-1295, sold under the research label "modified GRF 1-29" or "CJC-1295 without DAC" depending on formulation, is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds the pituitary GHRH receptor and stimulates pulsatile release of endogenous growth hormone (GH). Typical compounded doses range from 100 mcg to 300 mcg subcutaneously, administered one to three times daily or before sleep to coincide with the natural GH pulse.

GH itself has broad physiological effects: it increases insulin-like growth factor-1 (IGF-1), promotes lipolysis, increases lean mass, and raises glomerular filtration rate (GFR). That last point matters when a patient is also taking a renally cleared drug like gabapentin.

How Gabapentin Works

Gabapentin (brand names Neurontin, Gralise, Horizant) binds the alpha-2-delta subunit of voltage-gated calcium channels in the dorsal horn and throughout the CNS, reducing excitatory neurotransmitter release. The FDA-approved label covers partial seizures, postherpetic neuralgia, and restless legs syndrome (Horizant formulation). Off-label use is widespread: neuropathic pain, anxiety, insomnia, and alcohol use disorder management are among the most common reasons clinicians prescribe it.

Gabapentin is absorbed through a saturable intestinal transporter (LAT1/SLC7A5), which means bioavailability falls as dose rises, from roughly 60% at 300 mg three times daily to around 35% at 1,600 mg three times daily. Once absorbed, it undergoes no hepatic metabolism and is excreted unchanged in the urine, with a half-life of 5 to 7 hours in adults with normal renal function.

Pharmacokinetic Interaction Risk: Low but Not Zero

There is no shared metabolic pathway between CJC-1295 and gabapentin. This section explains why, and where a pharmacokinetic signal could still emerge indirectly.

CJC-1295 and CYP450 Enzymes

CJC-1295 is a 30-amino-acid peptide. Like all peptides above roughly 500 daltons, it is broken down by endogenous proteases, not by hepatic CYP1A2, CYP2C9, CYP2D6, or CYP3A4 enzymes. No P-glycoprotein interaction has been identified in published literature. This means CJC-1295 will not inhibit or induce the enzymes that process gabapentin. Gabapentin, for its part, is also free of CYP metabolism, so neither drug is likely to change the blood concentration of the other through a classic pharmacokinetic pathway.

The Indirect Renal Channel

Here is where the picture gets more nuanced. Chronic GH elevation from sustained GHRH stimulation raises GFR in healthy adults. A 2001 study by Johannsson et al. Published in the Journal of Clinical Endocrinology and Metabolism found that GH replacement in GH-deficient adults increased GFR by roughly 10 to 15% over six months. Because gabapentin clearance tracks almost perfectly with creatinine clearance, a GFR increase of that magnitude could modestly lower steady-state gabapentin plasma levels. The clinical consequence is likely minor in most patients, but in someone whose gabapentin was carefully titrated for seizure control, even a 10 to 15% shift in drug exposure warrants awareness.

Conversely, if a patient has pre-existing chronic kidney disease (CKD), gabapentin accumulates and the sedation risk rises substantially. The FDA gabapentin label requires dose reduction in patients with creatinine clearance below 60 mL/min. Prescribers adding CJC-1295 to such a patient's regimen should obtain a baseline comprehensive metabolic panel and recheck renal function at 60 to 90 days.

Pharmacodynamic Interaction Risk: Moderate

The CNS overlap is the part of this interaction that deserves the most attention at the clinical encounter.

Sedation Pathways

Gabapentin produces dose-dependent sedation, dizziness, and ataxia. The FDA label for Neurontin lists somnolence in 19.3% of epilepsy patients on 1,800 mg/day versus 8.7% on placebo, and dizziness in 17.1% versus 6.9%. These rates climb when gabapentin is combined with other CNS depressants.

CJC-1295 is not primarily categorized as a CNS depressant. GH secretagogues, however, do have sleep-modulating properties. Endogenous GHRH promotes slow-wave sleep, and exogenous GHRH analogues may deepen sleep in a dose-dependent manner. A study by Obál and Krueger published in Frontiers in Bioscience (2003) documented that GHRH microinjections into the anterior hypothalamus increased non-REM sleep duration in rats. Whether compounded CJC-1295 at clinical doses produces the same effect in humans has not been studied in randomized trials, but the biological plausibility is real.

When these two agents overlap on the same night, the combined CNS depression could be additive. Patients who inject CJC-1295 before bed (the most common protocol, designed to amplify the nocturnal GH pulse) and who take gabapentin at bedtime for neuropathic pain or insomnia are at the highest risk for next-morning grogginess, impaired driving ability, and, in older or opioid-using patients, respiratory depression.

Respiratory Depression Consideration

The FDA issued a Drug Safety Communication in December 2019 warning that gabapentinoids (gabapentin and pregabalin) carry a risk of serious breathing difficulties, especially when combined with CNS depressants or in patients with respiratory compromise. The agency reviewed 49 cases of respiratory depression, 12 of which were fatal. While CJC-1295 is not named in that communication, any agent that deepens sleep or reduces arousal threshold theoretically worsens the same physiological context.

Patients with obstructive sleep apnea (OSA) are particularly relevant here. GH therapy is known to worsen or unmask OSA in some individuals, and OSA is already a contraindication or strong caution for GH secretagogue use in most clinical protocols. Adding gabapentin to that scenario amplifies risk further.

Drug-Alcohol-Peptide Triangle

A patient who drinks alcohol, takes gabapentin, and uses CJC-1295 is stacking three CNS-overlapping exposures. Alcohol acutely suppresses GH secretion through a GHRH-independent mechanism, reducing the efficacy of CJC-1295 at the same time as it magnifies gabapentin's sedation. This is not a theoretical concern. A 1993 study by Ekman et al. In Clinical Endocrinology showed that acute ethanol ingestion blunted GH response to GHRH by approximately 50%. Patients should be counseled to avoid alcohol on evenings when both drugs are used.

Who Is at Highest Risk?

Not every patient combining CJC-1295 and gabapentin faces the same level of risk. The following factors significantly raise the clinical concern.

High-Risk Patient Profiles

Patients over age 65 face slower gabapentin clearance due to age-related GFR decline, and older adults are more sensitive to CNS depressants in general. Patients with CKD (creatinine clearance <60 mL/min) accumulate gabapentin and should have doses adjusted per the FDA label before any GH secretagogue is added. Patients already on opioids, benzodiazepines, muscle relaxants, or sedating antihistamines carry a compounded sedation burden that makes even moderate CJC-1295 use risky without clinical oversight.

Patients with untreated or undertreated OSA are a specific subset where most experienced peptide prescribers would pause or require a sleep study before proceeding with any GH-stimulating agent.

Lower-Risk Patient Profiles

A 35-year-old with normal renal function, no OSA, no other CNS depressants, and a daytime gabapentin schedule (300 mg three times daily for neuropathic pain) who is also using low-dose CJC-1295 in the morning faces a much smaller interaction signal. The pharmacodynamic overlap is timing-dependent. Separating gabapentin's last dose of the day from the CJC-1295 injection by at least four to six hours reduces, though does not eliminate, concurrent CNS effects.

Monitoring Parameters

The following monitoring framework is designed for clinicians managing patients who are using both agents concurrently. It is organized by timing and test type.

Baseline (Before Starting or Combining)

• Comprehensive metabolic panel (CMP) including creatinine and eGFR.
• Fasting IGF-1 level to establish GH-axis baseline.
• Epworth Sleepiness Scale (ESS) score or similar validated tool for daytime sleepiness.
• Confirm current medication list for any additional CNS depressants.
• Sleep apnea screening (STOP-BANG questionnaire minimum; polysomnography if score is 3 or higher).

At 30 Days

• Repeat ESS score. An increase of 3 or more points from baseline warrants a medication review.
• Patient self-report of dizziness, falls, or impaired morning alertness.
• Gabapentin dose review: if renal function is improving due to GH effects, consider whether the current gabapentin dose is still appropriate for the condition being treated.

At 60 to 90 Days

• Repeat CMP and eGFR.
• Fasting IGF-1 (target range for most adult protocols: 150 to 300 ng/mL; exceeding the upper limit of the age-adjusted normal range increases adverse-effect risk).
• Review of any changes in alcohol use, opioid prescriptions, or over-the-counter sleep aids.

Dose and Timing Strategies to Reduce Risk

Separating doses by time of day is the simplest risk-reduction step available without requiring a formulation change.

Timing CJC-1295 Injections

Most CJC-1295 protocols recommend pre-sleep injection (30 to 60 minutes before bed) to amplify the natural nocturnal GH pulse. If a patient takes gabapentin at bedtime for insomnia or neuropathic pain, this creates direct temporal overlap of two CNS-active agents. Shifting CJC-1295 to a morning injection eliminates that specific overlap. Morning GH pulses are smaller than nocturnal ones, which may reduce efficacy modestly, but the safety margin improvement justifies the trade-off in higher-risk patients.

Alternatively, if the clinical rationale for pre-sleep CJC-1295 is strong, the gabapentin dose can be moved to late afternoon (taking the last dose by 6 to 7 PM), allowing roughly two half-lives of clearance before the peptide injection.

Gabapentin Dose Adjustment

The FDA label for Neurontin provides specific creatinine clearance-based dosing tables. Patients with CrCl of 30 to 59 mL/min should receive 200 to 700 mg twice daily (total daily dose), not the standard three-times-daily regimen. If CJC-1295 raises GFR over time, a previously stable gabapentin dose may need upward adjustment to maintain therapeutic effect for seizure or pain management. This is the reverse of the typical drug-interaction concern (toxicity) and equally worth tracking.

What the Guidelines Say

No dedicated clinical guideline from the Endocrine Society, the American Association of Clinical Endocrinology (AACE), or the FDA addresses CJC-1295 specifically, because it is a compounded peptide without an approved New Drug Application. The closest applicable guidance comes from two directions.

The Endocrine Society's 2011 Clinical Practice Guideline on adult GH deficiency states: "GH therapy should not be started in the presence of active malignancy, diabetic retinopathy, or severe non-malignant illness. Patients with sleep apnea should be treated before initiating GH therapy." While this guideline addresses recombinant GH (somatropin) rather than secretagogues, most experienced peptide clinicians apply the same contraindication logic to GHRH analogues.

The FDA's gabapentin prescribing information states directly: "Patients should be counseled that gabapentin may cause somnolence, dizziness, and other symptoms and signs of CNS depression. Multi-drug regimens that include CNS depressants should be reviewed carefully."

These two pieces of guidance, read together, create a clear clinical obligation: review the full CNS depressant burden before adding CJC-1295 to a gabapentin regimen or vice versa.

Patient Counseling Points

Clear language at the point of prescribing reduces adverse events more reliably than any monitoring schedule alone.

What to Tell Patients Directly

Tell patients that both agents can make them sleepy and that the combination, especially the first few nights, may produce stronger sedation than either drug alone. They should not drive or operate machinery within eight hours of using both agents on the same evening. They should report next-morning grogginess, unusual vivid dreams, or feeling "foggy" for more than an hour after waking.

Patients should be told that alcohol significantly worsens both effects and is best avoided on evenings when either drug is used. If a patient is also using other peptides (such as ipamorelin, sermorelin, or BPC-157), the prescriber should be informed, because some stacks are more likely to produce systemic GH elevations that affect renal and CNS physiology.

When to Call the Clinic Immediately

Patients should contact the clinic immediately if they experience difficulty breathing during sleep (witnessed by a partner), unusual falls, syncope, or a seizure, even in someone with a known seizure disorder on stable gabapentin. These symptoms in the context of a new or recently changed peptide protocol warrant urgent re-evaluation.

CJC-1295 Drug Interactions Beyond Gabapentin

Gabapentin is not the only drug class worth examining alongside CJC-1295. Knowing the broader interaction profile helps contextualize gabapentin's position within it.

Insulin and Oral Hypoglycemics

GH is physiologically insulin-antagonistic. Sustained GH elevation from CJC-1295 may increase fasting glucose and reduce insulin sensitivity. Patients on insulin, metformin, GLP-1 receptor agonists (semaglutide, tirzepatide), or SGLT-2 inhibitors should monitor fasting glucose more frequently during the first 60 to 90 days on a GH secretagogue. The American Diabetes Association Standards of Care recommend HbA1c monitoring every three months when a new agent affecting glucose metabolism is added.

Corticosteroids

Glucocorticoids blunt the GH axis at multiple levels: they reduce GHRH receptor sensitivity, suppress IGF-1 production, and increase somatostatin tone. Patients on chronic prednisone or dexamethasone may see reduced CJC-1295 efficacy. Conversely, GH itself has anti-inflammatory properties, and patients on corticosteroids for inflammatory conditions should inform their prescriber of any peptide use.

Thyroid Hormone

GH stimulates peripheral conversion of T4 to T3. Patients on levothyroxine who start CJC-1295 may find that their previously stable thyroid replacement becomes relatively less effective, because rising T3 conversion may alter the feedback dynamics. A TSH check at 60 to 90 days is a reasonable precaution in this population.